Table 1 Patient and treatment characteristics
Characteristic | All patients n = 45 n (%) | RC48 n = 20 n (%) | RC48 + ICIs n = 25 n (%) | P |
|---|---|---|---|---|
Age | Â | Â | Â | 0.202 |
 Median (range) | 62(45–86) | 59(45–86) | 65(48–82) |  |
 ≥ 60 | 25(55.6) | 9(45.0) | 16(64.0) |  |
 < 60 | 20(44.4) | 11(55.5) | 9(36.0) |  |
Sex | Â | Â | Â | 0.885 |
 Male | 31(68.9) | 14(70.0) | 17(68.0) |  |
 Female | 14(31.1) | 6(30.0) | 8(32.0) |  |
ECOG | Â | Â | Â | 0.438 |
 0–1 | 34(75.6) | 14(70.0) | 20(80.0) |  |
 2 | 11(24.4) | 6(30.0) | 5(20.0) |  |
Primary tumor site | Â | Â | Â | 0.944 |
 Gastric | 29(64.4) | 13(65.0) | 16(64.0) |  |
 GEJ | 16(35.6) | 7(35.0) | 9(36.0) |  |
Metastatic site | Â | Â | Â | 0.524 |
 Lymph node | 31(68.9) | 15(75.0) | 16(64.0) |  |
 Liver | 22(48.9) | 9(45.0) | 13(52.0) |  |
 Peritoneum | 11(24.4) | 4(20.0) | 7(28.0) |  |
 Lung | 12(26.7) | 8(40.0) | 4(16.0) |  |
 Others | 23(51.1) | 9(45.0) | 14(56.0) |  |
Number of metastatic sites | Â | Â | Â | 0.540 |
 1–2 | 27(60.0) | 11(55.0) | 16(64.0) |  |
 ≥ 3 | 18(40.0) | 9(45.0) | 9(36.0) |  |
Prior surgery | Â | Â | Â | 0.641 |
 Yes | 23(51.1) | 11(55.0) | 12(48.0) |  |
 No | 22(48.9) | 9(45.0) | 13(52.0) |  |
HER-2 status | Â | Â | Â | 0.366 |
 Positive | 33(73.3) | 16(80.0) | 17(68.0) |  |
 HER2-low | 12(26.7) | 4(20.0) | 8(32.0) |  |
MSI status | Â | Â | Â | 0.556 |
 pMMR or MSS | 39(86.7) | 18(90.0) | 21(84.0) |  |
 Unknown | 6(13.3) | 2(10.0) | 4(16.0) |  |
Previous treatment agents | Â | Â | Â | 0.715 |
 Trastuzumab | 33(73.3) | 16(80.0) | 17(68.0) |  |
 Taxane | 29(64.4) | 14(70.0) | 15(60.0) |  |
 Irinotecan | 16(35.6) | 11(55.0) | 5(20.0) |  |
 Platinum | 37(82.2) | 17(85.0) | 20(80.0) |  |
 5-Fluorouracil | 39(86.7) | 16(80.0) | 23(92.0) |  |
 Antiangiogenic agents | 16(35.6) | 7(35.0) | 9(36.0) |  |
 ICIs | 26(57.8) | 12(60.0) | 14(56.0) |  |